Janssen Biotech, Inc.

Cephalon, Inc.

Christopher O'Brien

James Zangrilli

Tushar Shah

Jacqueline Perrigoue

Matthew Germinaro

Katherine Li

Omoniyi Adedokun

Richard Strauss

Hongyan Zhang

Guy Brusselle

Marion Vetter

Jewel Johanns

Colleen Marano

Kimberly Shields-Tuttle

A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor, such as an anti-TNF-α antibody (e.g., golimumab).

Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-&#x3b1; inhibitor, such as an anti-TNF-&#x3b1; antibody (e.g., golimumab).

Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody

Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to the patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/&#x3bc;L.

Use of reslizumab to treat moderate to severe eosinophilic asthma

Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to a patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/&#x3bc;L.

Growing community of inventors

Lafayette Hill, PA, United States of America

Christopher O'Brien